Heading for LabAutomation 2009 in Palm Springs, I was sure I would get a pulse on what folks in the industry felt about the financial crisis. But if I went with plenty of questions, I probably came back with a whole bunch more.
Endo Pharmaceuticals announced earlier this month that it entered into a merger agreement with Indevus Pharmaceuticals for $4.50 per share or $370 million in cash.